pharma news today glp-1 obesity drug Market: the rapid growth of the diabetes and drugs market GLP-1 drugs changed the obesity

The study is also observational, which means it cant prove cause and effect

GLP-1 receptor signaling in pancreatic alpha cells reduces glucagon secretion, further contributing to glucose lowering

What weve seen so far is that theres not too much difference between the diabetes costs for the oral and the injectable versions, says Tim Blackstock, a pharmaceutical industry analyst at Citeline

But ultimately, says Unitt, it will depend how they perform in the clinic

Common issues include nausea and diarrhea, but complications can also extend to conditions such as gastroesophageal reflux disease, gastroparesis (paralysis of the stomach), and colonic inflammation

Supplements can support these efforts, but they cannot replace them